Exercise-induced modulation of neuroinflammation in ageing https://t.co/MkS4tTm0mC

Among hypertensive patients with high cardiovascular risk, lowering systolic blood pressure with a target of <120 mm Hg compared with <140 mm Hg has a favorable impact on retinal microvasculature. https://t.co/LFNfJXzFjh #GWICC #AHS2025 #ACCIntl #JACC #Hypertension

Currently live at #eSPACEHF2025! Plenary Session 4 – Managing Cardiomyopathy in Heart Failure is underway. Prof. Giuseppe Rosano and Dr. Pedro Schwartzmann, MD PhD opened with key clinical approaches to cardiomyopathies in HF. Prof. Maurizio Pieroni finished presenting on

Session 4 Wrap-Up – Managing Cardiomyopathy in Heart Failure We just concluded Session 4 of #eSPACEHF2025, chaired by Prof. Giuseppe Rosano and Dr. Pedro Schwartzmann, focusing on the complexities of cardiomyopathies in HF. Prof. Maurizio Pieroni opened with Heart Failure in

β-blockers safe pre-discharge in #HFrEF #COPERNICUS ☠️ benefit in recent decomp https://t.co/RPAODKmbNj #STRONGHF rapid uptritration ⬇️ events https://t.co/2EGk0obyDg #IMPACTHF ⬆️ Rx persistence https://t.co/pc0wJkfY7U #BCONVINCED stopping not helpful https://t.co/GdMoEu5qr8

🔥 New in @NatureMedicine How do you communicate lifetime benefits expected with HFpEF therapies? New data from 3 RCTs (#DELIVER #FINEARTS #PARAGON) estimate up to *5 years* of event-free survival w combination Rx #GDMT for HFpEF has finally arrived! 🔗 https://t.co/ozSx3UwkLN

Transthyretin amyloid cardiomyopathy: from cause to novel treatments. Read this State-of-the-Art review just published in #EHJ 👉 https://t.co/xs8gK2WEW0 @RoccoMontone @ehj_ed #amyloidosis

Artificial Intelligence–Enabled Quantitative Coronary Plaque and Hemodynamic Analysis for Predicting Acute Coronary Syndrome AI-enabled plaque and hemodynamic quantification enhanced the predictability for ACS culprit lesions over the conventional coronary CTA analysis.

🔥New Scientific Statement from #HFA & #HFAI: SGLT2 inhibitors for the prevention & treatment of #HeartFailure Key recommendations across the HF spectrum: 📍At risk for HF: ⬇️HF events in patients with #T2DM & #CKD, initiate #SGLT2i 📍Post-AMI: ⬇️HFh alone, consider in

New therapeutic targets in heart failure: the role of RNA-binding proteins: read the news in #EHJ! #heart #failure #therapy #EHJ #cardiotwitter @ESC_jorunals @escardio https://t.co/AL6qA93ZEV

Albuminuria in Cardiovascular, Kidney, and Metabolic Disorders: A State-of-the-Art Review Urinary albumin-to-creatinine ratio is an attractive, unifying biomarker of cardiovascular, kidney, and metabolic conditions that may be useful for identifying and monitoring disease

Exercise Training in Heart Failure: Clinical Benefits and Mechanisms https://t.co/JGOzKPJY4n

Strengthening the Case for Earlier LDL-C Lowering 1️⃣ Even with CAC = 0, higher LDL-C was linked to more non-calcified plaque and greater CHD risk. 2️⃣ Each 1 mmol/L (≈38.7 mg/dL) higher LDL-C raised the risk of MI by 26% and CHD events by 28%. 3️⃣ Findings reinforce the

High blood pressure is the most prevalent and modifiable risk factor for the development of cardiovascular diseases, including coronary artery disease, heart failure, atrial fibrillation, stroke, dementia, chronic kidney disease, and all-cause mortality. This reflects several

🎯 Precision Lipidology Enters the RNA Era Small interfering RNAs (siRNAs) and antisense oligonucleotides (ASOs) are reshaping lipid management by targeting mRNA degradation at the source. 👉Inclisiran targets PCSK9 → ↓LDL-C 👉Volanesorsen, Olezarsen, Plozasiran target

Aldosterone and Aldosterone Modulation in Cardio-Kidney Diseases Partial agonists of the MR and directly attenuating aldosterone production using selective aldosterone synthase inhibitors is an emerging approach for patients with HF, CKD, and uncontrolled and resistant arterial

Wow, the game has changed! #SURPASSCVOT meets its primary & secondary endpoints in first *head-to-head* CV outcomes trial! Tirzepatide (dual GLP1/GIP agonist) vs Dulaglutide (GLP-1RA) including 16% lower risk of all cause mortality! https://t.co/rUFYZVn41N

🩺 Every hypertrophic wall has a story 💭🤔 ECG, echo, CMR & genetics can reveal: – HCM – Amyloidosis – Fabry – Mitochondrial or syndromic disease Red flags 🚩guide precision treatment. #Cardiology #HypertrophicCardiomyopathy #MedTwitter #StateOfTheArt

💊💥 New trial, new strategy: Dapagliflozin + spironolactone packs a bigger biomarker punch in #HFpEF. But what’s the trade-off? Kidney function takes a hit. The SOGALDI-PEF trial stirs up the combo therapy debate. https://t.co/t7wF6f07ii #HeartFailure #SGLT2i #NTproBNP #JACC

Primary Left Atrial Cardiopathy in Transthyretin Amyloidosis Cardiomyopathy by Multimodality Imaging: Implications for Thrombotic Events Primary LA cardiopathy seems to be associated with TEs in ATTR-CM, independently of AF, CHA2DS2-VASc, and LA dilatation, unlike other LVH